WuXi Biologics and Hangzhou DAC signed research service agreement with Aadi Bioscience on three novel ADCs

CAR-T Digest - August 2020

20 Dec 2024: WuXi Biologics and Hangzhou DAC signed research service agreement with Aadi Bioscience on three novel ADCs

WuXi Biologics and Hangzhou DAC Biotechnology have signed a research service agreement with Aadi Bioscience for a three-asset portfolio of preclinical next-wave ADCs
Aadi Bioscience will pay WuXi Biologics and Hangzhou DAC $44 million in upfront payments for the three assets, along with potential development milestone payments of up to $265 million, commercial milestone payments of up to $540 million, and single-digit royalties on sales
The three assets were developed through a collaboration between WuXi Biologics, which provided an antibody discovery platform, and Hangzhou DAC, which contributed advanced linker-payload technology
The portfolio targets cancer therapies, specifically aiming to improve outcomes for patients by building upon the successes of first-generation ADCs, with a focus on broadly expressed tumor targets